Phase III, Open-label, Multicentre, Randomised Trial to Establish Safety and Efficacy of an EGF Cancer Vaccine in Inoperable, Late Stage (IIIb/IV) NSCLC Patients Eligible to Receive Standard Treatment and Supportive Care.

Trial Profile

Phase III, Open-label, Multicentre, Randomised Trial to Establish Safety and Efficacy of an EGF Cancer Vaccine in Inoperable, Late Stage (IIIb/IV) NSCLC Patients Eligible to Receive Standard Treatment and Supportive Care.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 22 Jul 2017

At a glance

  • Drugs BV NSCLC 001 (Primary)
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Bioven
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 21 Mar 2014 Trial status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 22 Mar 2013 Interim results are expected to be available in the first half of 2014, according to a Bioven media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top